Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis

Summary Background Our aim was to determine whether drug-eluting stents are good value for money in long-term, everyday practice. Methods We did an 18-month cost-effectiveness analysis of the Basel Stent KostenEffektivitäts Trial (BASKET), which randomised 826 patients 2:1 to drug-eluting stents (n=...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2007-11, Vol.370 (9598), p.1552-1559
Main Authors: Rocca, Hans Peter Brunner-La, MD, Kaiser, Christoph, MD, Bernheim, Alain, MD, Zellweger, Michael J, MD, Jeger, Raban, MD, Buser, Peter T, Prof, Osswald, Stefan, Prof, Pfisterer, Matthias, Prof
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Aged
Angioplasty, Balloon, Coronary
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - economics
Biological and medical sciences
Clinical outcomes
Coronary Disease - economics
Coronary Disease - prevention & control
Coronary Disease - therapy
Cost-Benefit Analysis
Costs
Effectiveness
Female
General aspects
Heart attacks
Humans
Independent sample
Internal Medicine
Male
Medical imaging
Medical sciences
Medical treatment
Metals
Middle Aged
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel - economics
Prices
Quality of life
Quality-Adjusted Life Years
Risk Factors
Sensitivity analysis
Sirolimus - administration & dosage
Sirolimus - adverse effects
Sirolimus - economics
Stents
Stents - adverse effects
Stents - economics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Our aim was to determine whether drug-eluting stents are good value for money in long-term, everyday practice. Methods We did an 18-month cost-effectiveness analysis of the Basel Stent KostenEffektivitäts Trial (BASKET), which randomised 826 patients 2:1 to drug-eluting stents (n=545) or to bare-metal stents (281). We used non-parametric bootstrap techniques to determine incremental cost-effectiveness ratios (ICERs) of drug-eluting versus bare-metal stents, to compare low-risk (≥3·0 mm stents in native vessels; n=558, 68%) and high-risk patients (
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(07)61660-2